Etanercept for Treatment-Resistant Psoriasis

Title: Refractory psoriasis treatment with etanercept
: Mahiques Santos L, et al.
Publication: Med Clin (Barc). 2005 Sep 24;125(10):371-3.

Etanercept is a protein that binds to tumor necrosis factor and blocks inflammatory response. The authors wanted to see whether etanercept can treat severe psoriasis that was resistant to conventional treatment.

The authors enrolled 22 patients and gave them etanercept 50 mg/week via injection for 6 months. The severity of the patients’ psoriasis was evaluated every month by PASI or Psoriasis Assessment and Severity Index.

The authors found that 96% of the patients have improved PASI scoring at early week 12 and this was maintained until week 12. Etanercept was well tolerated without any significant side effects. The authors found that the patients had an average time until relapse of psoriasis of 2.27 +/- 0.59 months.

The authors concluded that etanercept seemed to be an effective therapy for severe cases of psoriasis that were refractory or resistant to other forms of treatments. However, they cautioned that long-term dosing and safety of etanercept in psoriasis were still needed.

Editor’s Note: Tumor necrosis factor is a protein produced by immune cells called macrophages, in response to toxins. It has been shown to be capable of attacking and destroying cancerous tumors.

Main Menu
Health Articles
Health News
Health Research
Site Map

Health Conditions
Cardiovascular Health
Digestive Health
Infectous Diseases
Musculoskeletal Health
Pregnancy & Childbirth
Skin Health

Misc. Health Articles
Presidential Diseases

Medical Research

Psoriasis Overview
Psoriasis Pictures
Research Summaries

©copyright 2004 - Health In Plain English. All Rights Reserved.

Health Articles Health News Health Research Explained in Plain English